Introduction
============

Inflammatory pain is one of the most common symptoms of the inflammatory disease and represents an important health problem. It is principally caused by the sensitization of primary nociceptive neurons by the direct action of inflammatory mediators (e.g., prostaglandins). In this context, pharmacologic control of inflammatory pain is mainly based on the use of nonsteroidal anti-inflammatory drugs (NSAIDs; aspirin and aspirin like drugs), which inhibits cyclooxygenase-derived prostaglandin production and, consequently, reduces nociceptor sensitization (Ferreira [@b22], [@b23]; Ferreira and Vane [@b24]). This effect ultimately prevents the development of hyperalgesia (decrease in nociceptive threshold) in humans and animals. However, NSAIDs are only partially effective and prolonged exposure can cause serious gastrointestinal (GI), renal, and cardiovascular side effects (Kashfi [@b31]). Thus, there is continuous effort to identify novel therapeutics for pain control that elicits fewer side effects.

A second strategy to control inflammatory pain is through the use of drugs, which are able to directly block ongoing nociceptor sensitization through peripheral actions (Lorenzetti and Ferreira [@b39]; Ferreira et al. [@b25]; Duarte et al. [@b20]). In fact, local administration of opioids and dipyrone reversed already established hyperalgesia induced by prostaglandin E~2~ (PGE~2~) (Ferreira [@b22]; Lorenzetti and Ferreira [@b40]). Therefore, in contrast to NSAIDs, drugs that act through the prevention of nociceptor sensitization by inhibiting prostaglandin synthesis are able to reverse ongoing inflammatory hyperalgesia.

In order to elucidate the mechanism involved in the directly blockage of ongoing inflammatory hyperalgesia, inhibitors of neuronal nitric oxide (NO) synthase as well as ATP-sensitive potassium channel (K~ATP~) potassium channels blockers prevented peripheral antinociception achieved with opioids and dipyrone (Rodrigues and Duarte [@b53]; Soares and Duarte [@b58]; Sachs et al. [@b56]). Therefore, it was suggested that this antinociceptive effect is mediated by NO and K~ATP~. Corroborating with this fact, the direct blockade of ongoing mechanical hyperalgesia has been observed after administration of NO donors, SNAP and sodium nitroprusside as well as K~ATP~ channels openers (Soares et al. [@b59]). Besides NO donors, it has also been described that hydrogen sulfide (H~2~S) donors are also able to directly block ongoing inflammatory hyperalgesia through the modulation of K~ATP~ currents (Distrutti et al. [@b17]; Zanardo et al. [@b64]; Cunha et al. [@b13]). Thus, these types of peripheral analgesics seem to act by restoring the threshold of nociceptors via the increase in K~ATP~ permeability promoting the hyperpolarization of primary nociceptive neurons (Distrutti et al. [@b17]; Cunha et al. [@b13]).

In attempt to enhance the activity of NSAIDs and to minimize their potential side effect, novel NSAIDs hybrids have been developed (Kashfi [@b31]; Qandil [@b52]). NO-releasing NSAIDs have been shown to be effective in preclinical models of inflammation with less side effects and they have been evaluated in several clinical trials (Schnitzer et al. [@b57]; Fiorucci and Distrutti [@b27]). Similarly, H~2~S-releasing NSAIDs have been shown to have anti-inflammatory properties (Kashfi and Olson [@b32]). Based on the scientific evidence that NO and H~2~S are gaseous mediators with physiological relevance, a new hybrid incorporating these two entities into an aspirin molecule was developed, the so-called NOSH-aspirin (Kodela et al. [@b34]). NOSH-aspirin was shown to be more efficient and/or powerful than traditional aspirin in several experimental models (Kodela et al. [@b34]). For instance, NOSH-aspirin was a potent inhibitor of colon cancer cell growth in vitro and in an in vivo model of human colon cancer xenografts in mice (Chattopadhyay et al. [@b7]). Furthermore, NOSH-aspirin was more potent than aspirin to attenuate microglial and astrocytes activation in an in vitro model of neuroinflammation (Lee et al. [@b35]). Based on the above evidences, in the present study we investigated the possible analgesic effects of NOSH-aspirin in several inflammatory models of pain, comparing it to aspirin.

Material and Methods
====================

Animals
-------

The experiments were performed on male Balb/C mice weighing between 20 and 30 g. The mice were housed in the animal care facility of the Ribeirao Preto Medical School and moved to the testing room at least 1 h before the experiments. Food and water were available ad libitum. Behavioral tests were performed on animals in a randomized order in a blind fashion in which the person who performed the treatments was not the same as one who made the behavioral assessment. Animal care and handling procedures were in accordance with the guidelines of the International Association for the Study of Pain (IASP) on the use of animals in pain research, and with the approval of the Ethics Committee of the Ribeirao Preto Medical School, University of São Paulo.

Chemicals and drugs
-------------------

The following drugs and chemicals were obtained from the sources indicated: PGE~2~, glib., complete Freund's adjuvant (CFA), aspirin and diazepam were from Sigma-Aldrich (St. Louis, MO); Cg (FMC Corp., Philadelphia, PA); acetic acid, dimethylsulfoxide (DMSO) and Tween 20 were from Merck (Darmstadt, Germany); NOSH-aspirin (Fig.[1](#fig01){ref-type="fig"}) \[4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl) oxy)benzoate\] was synthesized and characterized as previously described (Kodela et al. [@b34]) and was a gift from Avicenna Pharmaceuticals (New York, NY). The drugs were prepared as follows: glib. was dissolved in 1% Tween 20 in saline; PGE~2~ was dissolved in 2% ethanol in saline; diazepam was dissolved in saline; aspirin and NOSH-aspirin were dissolved in DMSO/Tween 20 and resuspended in saline. The final concentrations of DMSO and Tween 20 were 5%.

![Structural components of NOSH-aspirin. The parent compound aspirin is shown in the shaded box. The parts of the molecule that releases NO and H~2~S are shown in the dotted ellipses. NO, nitric oxide; H~2~S, hydrogen sulfide.](prp20003-e00133-f1){#fig01}

Acetic acid-induced writhing test
---------------------------------

Mice were treated by gavage (p.o.) with aspirin (5, 15 or 150 *μ*mol/kg), NOSH-aspirin (5, 15, or 150 *μ*mol/kg) or vehicle an hour before testing. Writhing responses were induced by intraperitoneal (i.p.) injection of acetic acid 0.8% (100 *μ*L per 10 g body weight). The numbers of writhing responses were counted during a 20-min period as reported previously (Collier et al. [@b8]). The writhing response consists of a contraction of the abdominal muscle together with a stretching of hind limbs. The inhibitory effects were calculated based on the effect of the vehicle.

Evaluation of mechanical hyperalgesia: electronic von Frey test
---------------------------------------------------------------

In this study, we have used the term hyperalgesia to describe the decrease in the mechanical nociceptive threshold of mice. Mechanical hyperalgesia was tested as previously reported (Cunha et al. [@b11]). Briefly, in a quiet room, mice were placed in acrylic cages (12 × 20 × 17 cm) with wire grid floors, 15--30 min before the start of the test. The test consisted of evoking a hind paw flexion reflex with a hand-held force transducer adapted with a 0.5-mm^2^ polypropylene tip for mice (Electronic von Frey; IITC Life Science, Woodland Hills, CA). A tilted mirror placed under the grid provided a clear view of the mice hind paw. The investigator was trained to apply the tip in between the five distal footpads with a gradual increase in pressure. The stimulus was automatically discontinued and its intensity recorded when the paw was withdrawn. The end-point was characterized by the removal of the paw in a clear flinch response after paw withdrawal. The animals were tested before and after treatments. A different investigator performed each test, as was the case in the preparation of solutions and treatment of the animals. The results are expressed by the Δ mechanical threshold (in grams, g), which was calculated by subtracting the average of the last three measurements after treatments from the average of three measurements before treatments.

Effect of NOSH-aspirin on inflammatory hyperalgesia
---------------------------------------------------

In attempt to compare the antinociceptive effects of aspirin and NOSH-aspirin on inflammatory hyperalgesia, initially, we evaluated the dose--response effects of these drugs against Cg-induced acute mechanical inflammatory hyperalgesia. The animals were pretreated (30 min before) with NOSH-aspirin (5, 50 and 150 *μ*mol/kg, p.o.), aspirin (5, 50, and 150 *μ*mol/kg, p.o.), or vehicle (p.o.) followed by intraplantar (i.p.) injection of Cg (100 *μ*g/paw). Mechanical hyperalgesia was determined 3 h after Cg injection using electronic von Frey. This time point corresponds to the maximal hyperalgesia produced by Cg. Furthermore, to evaluate the effect of these drugs on long-lasting mechanical inflammatory hyperalgesia, CFA was injected first (10 *μ*L/paw), after 24 h the animals were treated orally with NOSH-aspirin (150 *μ*mol/kg, p.o.), aspirin (150 *μ*mol/kg, p.o.) or vehicle and then mechanical hyperalgesia was evaluated at 1, 3, 5, 7, and 24 h post drugs treatment as described above. As a control we used i.p. injection of saline.

Effect of NOSH-aspirin on hyperalgesia produced by a directly acting hyperalgesic mediator: involvement of K~ATP~
-----------------------------------------------------------------------------------------------------------------

In attempting to verify whether NOSH-aspirin was able to affect hyperalgesia produced by a directly acting mediator, its effect on PGE~2~-induced hyperalgesia was evaluated. Mice were pretreated 50 min before with aspirin (150 *μ*mol/kg), NOSH-aspirin (150 *μ*mol/kg) or vehicle orally followed by i.p. injection of PGE~2~ (100 ng/paw). Mechanical hyperalgesia was evaluated 60 min after injection of PGE~2~, which correspond to the maximal hyperalgesic response produced by PGE~2~ (Cunha et al. [@b14]). To ascertain whether the actions of NOSH-aspirin were mediated through K~ATP~, mice were pretreated with a K~ATP~ blocker, glib. (10 mg/kg, i.p.) and after 30 min, they received vehicle or NOSH-aspirin (150 *μ*mol/kg) orally. After 50 min all groups received i.p. injection of PGE~2~. Mechanical hyperalgesia was evaluated 60 min after injection of PGE~2~.

Determination of neutrophil accumulation in the inflammatory site
-----------------------------------------------------------------

Myeloperoxidase (MPO) activity was used as an index of neutrophil accumulation in the mice's plantar tissues, based on a kinetic-colorimetric assay as described previously (Bradley et al. [@b5]). Mice were pretreated with NOSH-aspirin (150 *μ*mol/kg, v.o.), aspirin (150 *μ*mol/kg, v.o.) or vehicle followed by i.p. injection of Cg (100 *μ*g/paw). Plantar tissue was harvested from the injected and control paws (saline). Samples were collected in 50 mmol/L K~2~HPO~4~ buffer (pH 6.0) containing 0.5% hexadecyl trimethylammonium bromide and kept at −80°C. Just before the assay, the tissue was homogenized using a Polytron (PT3100) and centrifuged at 13,000 *g* for 4 min. In our experimental condition (low pH), the MPO assay did not detect the activity of this enzyme in mononuclear cells. To prepare the solution for the analysis, 5 *μ*L of the supernatant was mixed with 200 *μ*L of phosphate buffer (50 mmol/L, pH 6.0), containing 0.167 mg/mL *O*-dianisidine dihydrochloride and 0.0005% hydrogen peroxide. The solution was analyzed by spectrophotometry for MPO activity determination at 450 nm (Spectra max, Molecular Devices, Sunnyvale CA, USA). The MPO activity was compared with a standard curve of neutrophils obtained from mice blood. The results were presented as number of neutrophils ×10^6^/mg tissue.

Cytokine measurements
---------------------

Mice were pretreated with NOSH-aspirin (150 *μ*mol/kg, v.o.), aspirin (150 *μ*mol/kg, v.o.) or vehicle orally followed by i.p. injection of Cg (100 *μ*g/paw). Plantar tissue was harvested from the injected and control paws (saline) 3 h after Cg injection. The time for cytokine measurement was defined based on the peak of the production of the analyzed cytokines (Cunha et al. [@b12]). The samples were triturated and homogenized in 300 *μ*L of the appropriate buffer containing protease inhibitors. The concentrations of the cytokines tumor necrosis factor-*α* (TNF-*α*), interleukin-1 beta (IL-1*β*), and keratinocyte-derived chemokine (KC/CXCL1) were determined as previously described by ELISA (Cunha et al. [@b12]) using paired antibodies (R&D Systems, Minneapolis, MN, USA). The results are expressed as pg/paw of each cytokine.

Measurement of motor performance
--------------------------------

In order to discard possible nonspecific muscle relaxant or sedative effects of NOSH-aspirin, mice motor performance was evaluated on the rota-rod test (Rosland et al. [@b54]). The apparatus consisted of a bar with a diameter of 2.5 cm, subdivided into six compartments by disks 25 cm in diameter (Model 7600; Ugo Basile, Varese, Italy). The bar rotated at a constant speed of 22 rotations per minute. The animals were selected 24 h previously by eliminating those mice that did not remain on the bar for two consecutive periods of 120 sec. Animals were treated orally with vehicle or NOSH-aspirin (150 *μ*mol/kg, v.o.). Diazepam (5 mg/kg, i.p.) was used as a positive control. The animal's latency to fall off was measured automatically by a mechanical sensor located in the floor of the apparatus. The cut-off time used was 120 sec.

Statistical analysis
--------------------

Data are reported as the means ± SEM and are representative of two separate experiments. The letter *n* in the legends refers to the number of mice used in the experimental group of each experiment. The differences between the experimental groups were compared by one-way analysis of variance (ANOVA), and individual comparisons were subsequently made with Tukey's post hoc test. Two-way ANOVA was used to compare the groups when the hypernociceptive responses were measured at different times after the stimulus injection. A value of *P *\<* *0.05 was considered significant.

Results
=======

NOSH-aspirin reduced acetic acid-induced writhing responses in mice: Comparison with aspirin
--------------------------------------------------------------------------------------------

Intraperitoneal injection of acetic acid-induced writhing response has been extensively used in the screening of novel analgesic drugs (Collier et al. [@b8]). Thus, this nociceptive behavior test was initially used to evaluate the possible antinociceptive effect of NOSH-aspirin in comparison to that of aspirin. NOSH-aspirin and aspirin were both effective in inhibiting acetic acid-induced writhing response in a dose-dependent manner (Fig.[2](#fig02){ref-type="fig"}). However, whereas only the highest dose of aspirin presented a significant effect, the low and intermediary doses of NOSH-aspirin were significantly effective in inhibiting the writhing responses (Fig.[2](#fig02){ref-type="fig"}). Regarding efficacy, at the highest dose tested (450 *μ*mol/kg), inhibition due to aspirin was ∼49%, while in the NOSH-aspirin-treated animals this effect reached ∼59% (Fig.[2](#fig02){ref-type="fig"}). Although NOSH-aspirin's effect was higher than aspirin at this dose no statistical difference (*P* = 0.089) was observed.

![Effect of NOSH-aspirin (NOSH-ASA) and aspirin on acetic acid-induced writhing responses in mice. Animals were pretreated orally (p.o.) with aspirin (5, 15, 150 *μ*mol/kg), NOSH-ASA (5, 15, 150, and 450 *μ*mol/kg) or vehicle (v), 50 min before the intraperitoneal administration of acetic acid (0.8%, i.p.). Writhing responses was assessed during 20 min after acetic acid injection. The graphic represents the percentage of inhibition relative to vehicle. Data are the means ± SEM (*n* = 7). \**P *\<* *0.05, \*\**P *\<* *0.01, and \*\*\**P *\<* *0.001 versus vehicle group.](prp20003-e00133-f2){#fig02}

NOSH-aspirin did not produce significant impairment in mice motor coordinance
-----------------------------------------------------------------------------

It is important to note that sedative agents may produce false-positive effects on the acetic acid-induced writhing response test (Lopes et al. [@b38]). In this context, we used the rota-rod test to evaluate whether the antinociceptive effect of NOSH-aspirin upon acetic acid-induced writhing response might be due to an unspecific effect on motor coordinance. Importantly, NOSH-aspirin (150 *μ*mol/kg, p.o.) did not change locomotor activity in all evaluated times. As a positive control, Diazepam produced significant motor impairment (Fig.[3](#fig03){ref-type="fig"}).

![Effect of NOSH-aspirin (NOSH-ASA) on motor coordinance. Mice were treated orally with NOSH-ASA (150 *μ*mol/kg, v.o.), diazepam (5 mg/kg, i.p.) (positive control) or vehicle and were subjected to Rota-rod test. Sections were performed before and 1, 3, and 5 h after treatments. Data are the means ± SEM (*n* = 6). \**P *\<* *0.05, \*\**P *\<* *0.01, and \*\*\**P *\<* *0.001 versus vehicle group.](prp20003-e00133-f3){#fig03}

NOSH-aspirin inhibits Cg- and CFA-induced inflammatory hyperalgesia: comparison with aspirin
--------------------------------------------------------------------------------------------

Further investigating the potential antinociceptive effect of NOSH-aspirin, we next evaluated its effect against Cg-induced acute inflammatory hyperalgesia (Joris et al. [@b30]). Aspirin and NOSH-aspirin treatments were also able to inhibit Cg-induced inflammatory hyperalgesia (Fig.[4A](#fig04){ref-type="fig"} and [B](#fig04){ref-type="fig"}). Similar to that observed in the acetic acid model, whereas the intermediary dose of NOSH-aspirin (50 *μ*mol/kg) produced a significant effect, only the higher dose of aspirin was able to reduce inflammatory hyperalgesia (Fig.[4C](#fig04){ref-type="fig"}). In terms of efficacy, at 50 *μ*mol/kg, hyperalgesic inhibition due to aspirin was ∼25%; whereas at the same dose, NOSH-aspirin caused a 50% inhibition (Fig.[4C](#fig04){ref-type="fig"}). At the highest dose tested (150 *μ*mol/kg), inhibition due to aspirin was ∼52%, while in the NOSH-aspirin-treated animals this effect reached ∼72% (Fig.[4C](#fig04){ref-type="fig"}).

![Effect of NOSH-aspirin (NOSH-ASA) and aspirin on carrageenan- and CFA-induced inflammatory hyperalgesia. Mice were pretreated with (A) aspirin (5, 50 and 150 *μ*mol/kg), (B) NOSH-ASA (5, 50, and 150 *μ*mol/kg) or vehicle (v) orally (p.o.) 30 min before the intraplantar injection of carrageenan (Cg; 100 *μ*g/paw). The hypernociceptive responses were evaluated 3 h after carrageenan injection. (C) Percentage of inhibition caused by aspirin and NOSH-ASA (150 *μ*mol/kg) upon carrageenan-induced hyperalgesia. (D) Animals received an injection of 10 *μ*L of CFA in the hind paw. At 24 h after, mechanical nociceptive threshold was evaluated followed by the treated with NOSH-ASA (150 *μ*mol/kg), aspirin (150 *μ*mol/kg) or vehicle (p.o.). Mechanical hyperalgesia was evaluated 1, 3, 5, 7, and 24 h after treatment. Data are the means ± SEM (*n* = 6). \**P *\<* *0.05, \*\**P *\<* *0.01, and \*\*\**P *\<* *0.001 versus vehicle-treated group. CFA, complete Freund's adjuvant.](prp20003-e00133-f4){#fig04}

In a therapeutic perspective, next we evaluated the posttreatment effect of NOSH-aspirin against CFA-induced inflammatory hyperalgesia. At 24 h after i.p. injection of CFA, mechanical hyperalgesia was measured followed by the treatment with vehicle, aspirin and NOSH-aspirin (150 *μ*mol/kg; Fig.[4D](#fig04){ref-type="fig"}). CFA-induced inflammatory hyperalgesia was reduced by the treatment with aspirin and NOSH-aspirin. However, the effect produced by NOSH-aspirin was initiated earlier, was greater in magnitude, and long lasting (Fig.[4D](#fig04){ref-type="fig"}).

Effect of NOSH-aspirin on Cg-induced neutrophil migration and pronociceptive cytokines production
-------------------------------------------------------------------------------------------------

In order to assess the mechanisms by which NOSH-aspirin further inhibits inflammatory hyperalgesia compared to aspirin, we next compared the effects of NOSH-aspirin and aspirin on Cg-induced neutrophil migration and pronociceptive cytokines production in the plantar tissue. Pretreatment with aspirin or NOSH-aspirin did not affect Cg-induced neutrophil migration in mice (Fig.[5A](#fig05){ref-type="fig"}). Although pretreatment with aspirin or NOSH-aspirin did not change the production of TNF-*α* (Fig.[5B](#fig05){ref-type="fig"}) or KC/CXCL1 (Fig.[5C](#fig05){ref-type="fig"}), NOSH-aspirin but not aspirin significantly reduced the production of IL-1*β* (Fig.[5D](#fig05){ref-type="fig"}) when compared to the vehicle-treated group. Thus, the enhanced antinociceptive effect promoted by NOSH-aspirin when compared with aspirin may in part be due to its ability to reduce IL-1-*β* production.

![Effect of NOSH-aspirin (NOSH-ASA) and aspirin on carrageenan-induced neutrophil migration and local production of pronociceptive cytokines. Mice were pretreated with aspirin (150 *μ*mol/kg), NOSH-ASA (150 *μ*mol/kg) or vehicle orally 30 min before the intraplantar injection of carrageenan (Cg; 100 *μ*g/paw) or saline. At 3 h after Cg injection plantar tissue were collected for measurement of (A) neutrophil migration (MPO activity assay) and the levels of (B) TNF-*α*, (C) KC/CXCL1, and (D) IL1-*β* by ELISA. Data are the means ± SEM (*n* = 6). \*\*\**P *\<* *0.001 versus saline group. ^\#^*P *\<* *0.05 versus vehicle-treated group. MPO, myeloperoxidase; TNF-*α,* tumor necrosis factor-*α;* KC/CXCL1, keratinocyte-derived chemokine.](prp20003-e00133-f5){#fig05}

NOSH-aspirin directly blocks PGE~2~-induced hyperalgesia: Involvement of K~ATP~ channels
----------------------------------------------------------------------------------------

NO and H~2~S are able to reduced inflammatory hyperalgesia by acting directly on neuronal excitability through modulation of K~ATP~ channels (Soares et al. [@b59]; Cunha et al. [@b13]). Therefore, in the next step we evaluated whether NOSH-aspirin was able to reduce hyperalgesia produced by a directly acting hyperalgesic mediator, PGE~2,~ and whether this effect was dependent on K~ATP~ channels modulation. First, it was observed that pretreatment with NOSH-aspirin, but not with aspirin, was able to reduce PGE~2~-induced mechanical hyperalgesia (Fig.[6A](#fig06){ref-type="fig"}). Furthermore, the antinociceptive effect of NOSH-aspirin upon PGE~2~-induced hyperalgesia was prevented when mice were treated with a K~ATP~ channels blocker (glib.) (Fig.[6B](#fig06){ref-type="fig"}). As a control, glibenclaminde alone caused no change in PGE~2~-induced hyperalgesia (Fig.[6B](#fig06){ref-type="fig"}). Therefore, these results further indicate that the additive effects of NOSH-aspirin over aspirin might be partially due to its direct effect on inflammatory hyperalgesia through up modulation of K~ATP~ currents.

![Effect of NOSH-aspirin (NOSH-ASA) and aspirin on PGE~2~-induced hyperalgesia: involvement of K~ATP~. (A) Mice were pretreated 50 min before with aspirin (150 *μ*mol/kg), NOSH-ASA (150 *μ*mol/kg) or vehicle (v) orally followed by intraplantar (i.p.) injection of PGE~2~. Mechanical hyperalgesia was evaluated 60 min after PGE~2~ injection. (B) Mice were pretreated with K~ATP~ blocker (glibenclamide; 10 mg/kg, i.p.) and after 30 min, they received vehicle or NOSH-ASA (150 *μ*mol/kg), and after 50 min all groups received i.p. injection of PGE~2~. Mechanical hyperalgesia was evaluated 60 min after PGE~2~ injection. Data are the means ± SEM (*n* = 6). \*\**P *\<* *0.01 and \*\*\**P *\<* *0.001 versus vehicle group, ^\#^*P *\<* *0.001 versus NOSH-ASA-treated group. K~ATP~, ATP-sensitive potassium channel; PGE~2~, prostaglandin E~2~.](prp20003-e00133-f6){#fig06}

Discussion
==========

NSAIDs are used to relive the most common forms of pain and in the United States over 30 million people use NSAIDs on a daily basis (American-Gastroenterological-Association [@b3]). However, their effective pain relief may at times be limited and their long-term use may lead to severe side effects, including GI, cardiovascular, and renal disorders (Ejaz et al. [@b21]; Patricio et al. [@b50]). Thus, developing NSAIDs that offer effective pain control with fewer or less serious adverse effects would be a valuable medical advance (Nalamachu et al. [@b48]). To address these potentially harmful effects, NOSH-aspirin (NBS-1120), a NO- and H~2~S-releasing hybrid was developed (Kodela et al. [@b34]). The rational for developing NOSH-aspirin was based on the observations that NO (Wallace and Miller [@b62]) and H~2~S (Fiorucci [@b26]) have some of the same properties as PGs within the gastric mucosa, thus modulating some components of the mucosal defense systems. NOSH-aspirin was shown to have potent anti-inflammatory properties (Kodela et al. [@b34]) and be devoid of any GI side effects (Nia et al. [@b49]). Herein, we provide evidence that NOSH-aspirin is a novel therapeutic agent for controlling inflammatory pain. It was more potent than aspirin, its parent compound and presents long-lasting effect, in producing analgesia in different experimental models of inflammatory pain. Moreover, it seems that NOSH-aspirin's-enhanced antinociceptive effect might be due to its ability to reduce the production of IL-1*β* and restore neuronal sensitization caused by PGE~2~ through upregulation of K~ATP~ channels, which was not observed with aspirin.

Initially, the acetic acid-induced writhing test was used to investigate the in vivo antinociceptive activity of NOSH-aspirin. This test is a visceral pain model that is widely used to evaluate antinociceptive activity of novel compounds (Morucci et al. [@b47]). In this model, nociceptive behaviors are generated through direct action of acetic acid on sensory neurons. However, endogenous mediators such as bradykinin, prostaglandins, and cytokines (TNF-*α* and IL-1*β*), may indirectly also cause sensory neurons sensitization and activation (Martinez et al. [@b43]). Oral administration of NOSH-aspirin reduced the number of writhes and its effect was more potent than aspirin. It is important to mention that in high doses there is only a tendency of NOSH-aspirin to be more efficacious that aspirin. The effect could be ascribed to the inhibition of prostaglandins production as previously shown (Chattopadhyay et al. [@b7]; Kodela et al. [@b34]). Moreover, NOSH-aspirin-derived NO could also be modulating pain sensitivity. In fact, the antinociceptive effects of several drugs in the acetic acid pain model are mediated thought endogenous production of NO (Staurengo-Ferrari et al. [@b60]).

In certain situations the analgesic effects of some drugs upon acetic acid-induced writhing can be confused with motor impairment or myorelaxant activities (Lopes et al. [@b38]). For NOSH-aspirin this is not the case, since it did not cause any alterations in the rota-rod test, which is a classical model to evaluate these unspecific effects (Rosland et al. [@b54]). Therefore, the antinociception effects of NOSH-aspirin do not appear to be through peripheral neuromuscular blockade or induction of sedation.

We also used Cg- and CFA-induced inflammatory hyperalgesia to assess the antinociceptive effects of NOSH-aspirin. Whereas the paw injection of Cg promotes acute inflammatory hyperalgesia which are very useful for mechanism of action studies, the CFA model is clinically more relevant due to its chronic character (Colpaert [@b9]). In fact, CFA-induced paw inflammation is accompanied by hyperalgesia, which is robust over several days (Ma and Woolf [@b42]). Furthermore, CFA-induced inflammatory hyperalgesia may be used to evaluate the pharmacokinetic profile of antinociceptive drugs. In this context, using the CFA-induced hyperalgesia it was possible to ascertain that NOSH-aspirin had an effect when given 24 h after stimulus injection, suggesting a therapeutic effect. In this model the antinociceptive effect of NOSH-aspirin seems to be longer lasting than aspirin.

The mechanisms involved in the sensitization of the primary sensory neurons, and consequently in the establishment of inflammatory hypernociception, may be divided into two phases. The first involves the nonneuronal events: the resident and migratory immune cells produce a vast number of hypernociceptive inflammatory mediators including pronociceptive cytokines TNF-*α*, IL-1*β,* and chemokines, nerve growth factor, and kinins, which trigger the release of directly acting hyperalgesic mediators (Verri et al. [@b61]). These mediators are considered direct acting because they activate their specific receptors on the membrane of primary nociceptive neurons (Cunha et al. [@b12]). Prostaglandins are known to be direct-acting hyperalgesic mediators. The second phase includes neuronal events: activation of the receptors on primary nociceptive neurons by direct-acting mediators leading to enhanced neuron excitability (Aley and Levine [@b1]). In order to elucidate the possible mechanisms by which NOSH-aspirin is superior to aspirin in inhibiting inflammatory hyperalgesia, initially the impact of NOSH-aspirin on the production of pronociceptive cytokines and neutrophil migration was determined. Firstly, NOSH-aspirin's-enhanced antinociceptive effect was not associated with reduction in neutrophil migration. These results might reflect the fact that NSAIDs do not interfere with leukocyte migration, but inhibit inflammatory hyperalgesia (Moncada et al. [@b44]; Lukkarinen et al. [@b41]). Furthermore, whereas NO is an important inhibitor of neutrophil migration to inflammatory site, H~2~S donors seems to enhance neutrophil migration in Cg-induced paw inflammation (Dal Secco et al. [@b16]; Bhatia et al. [@b4]; Cunha and Verri [@b10]). Thus, with NOSH-aspirin there appears to be a balance between pro- and antineutrophil migration factors and in the last instance neutrophil migration is not altered. Nevertheless, it is noteworthy that the effects of NO and H~2~S upon neutrophil migration is concentration dependent (Bhatia et al. [@b4]; Distrutti et al. [@b18]; Li et al. [@b36]; Kawabata et al. [@b33]; Cunha et al. [@b13]).

Inflammatory hyperalgesia is mediated by the production of a cascade of pronociceptive cytokines/chemokines, including TNF-*α*, IL-*β,* and KC/CXCCL1 (Cunha et al. [@b12], [@b14]). Further evaluating the mechanisms by which NOSH-aspirin is different to aspirin, their effect upon Cg-induced pronociceptive cytokines release was determined. Interestingly, whereas both did not alter the in vivo production of TNF-*α* and KC/CXCCL1, NOSH-aspirin, but not aspirin, was able to reduce the production/release of IL-1*β*. Although, we have previously shown that NaHS, another H~2~S donor, did not reduce the production of any of these cytokines in the mice paw during Cg-induced paw inflammation (Cunha et al. [@b13]), the literature suggests that H~2~S can modulate pronociceptive cytokines production (Li et al. [@b37]; Lee et al. [@b35]). In addition, there is evidence that drugs, which promote peripheral antinociceptive action through increases in NO, modulate the production of IL-1*β* (Zarpelon et al. [@b65]). Moreover, NO-releasing NSAIDs reduce the activation of NF-*κ*B, which is an important transcription factor involved in the production of IL-1*β* (Chattopadhyay et al. [@b6]; Lee et al. [@b35]). Thus, the effect of NOSH-aspirin on IL-1*β* production could be ascribed to the released NO, or even by an additive (or synergistic) effect of both.

The main mechanism by which NSAIDs reduce inflammatory hyperalgesia is inhibiting the production of inflammatory mediators (Ferreira [@b22]), and preventing the sensitization of primary nociceptive neurons (Ferreira [@b22]; Moncada et al. [@b45]). However, there are some analgesics that act on the periphery, thus directly blocking nociceptive neurons sensitization (Ferreira et al. [@b25]; Duarte et al. [@b20]). These analgesics have the characteristics of inhibiting PGE~2~-induced hyperalgesia, suggesting they might be restoring neuronal excitability (Alves et al. [@b2]; Cunha et al. [@b15]). This appears to be the case for NOSH-aspirin, because it reduced the production of pronociceptive cytokines and inhibited mechanical hyperalgesia triggered by PGE~2~. In agreement, NO- and H~2~S-donors unlike NSAIDs are able to reduce PGE~2~-induced hyperalgesia (Cunha et al. [@b13], [@b15]).

The mechanism by which NOSH-aspirin and other H~2~S-donors inhibit PGE~2~-induced hyperalgesia seems to be dependent on upregulation of K~ATP~ currents in the primary nociceptive neurons (Distrutti et al. [@b17]; Cunha et al. [@b13], [@b15]), leading to the hyperpolarization of primary nociceptive neurons (Cunha et al. [@b15]). There are also data showing that H~2~S hyperpolarizes dorsal raphe neurons by activating the ATP-sensitive K~ATP~ channels (Moore et al. [@b46]). Thus, the potent and efficacious effect of NOSH-aspirin against inflammatory pain is due to its ability to prevent and restore nociceptive neurons sensitization. Although our main hypothesis is that NOSH-aspirin is acting peripherally to reduce inflammatory pain, we must also acknowledge that it could be promoting analgesia by acting centrally. In this context, we like to point out a recent study by Distrutti et al. ([@b19]) suggesting that the antinociception effects of H~2~S in a rodent model of visceral pain was modulated by the transactivation of mu opioid receptors.

From a therapeutic point of view, it should be stressed that NSAIDs can have serious side effects including GI, cardiovascular, and renal (Kashfi [@b31]). Several studies have shown that H~2~S and NO are important mediators of gastric mucosal protection (Phillipson et al. [@b51]; Fiorucci et al. [@b28]). In agreement with these findings, NOSH-aspirin which releases both NO and H~2~S (Chattopadhyay et al. [@b7]; Kodela et al. [@b34]) has been shown to be safe to the stomach (Nia et al. [@b49]). It addition to its GI safety, NOSH-aspirin might also prove to have enhanced cardiovascular and renal safety profiles. This is because NO and H~2~S have protective roles in the cardiovascular and renal system (Wallace et al. [@b63]; Huledal et al. [@b29]; Rossoni et al. [@b55]).

In summary, the present results indicate that NOSH-aspirin offers greater potency than aspirin in reducing inflammatory pain in several clinically relevant models. The enhanced antinociceptive effect of NOSH-aspirin appears to be due to its ability to reduce the production of pronociceptive cytokines such as IL-1*β*. Furthermore, NOSH-aspirin is also able to reduce hyperalgesia, caused by a directly acting hyperalgesic mediator in a mechanism dependent on modulation of K~ATP~ channels. In conclusion, we would like to suggest that NOSH-aspirin represents a prototype of a new class of analgesic drugs with more potent effects than the traditional NSAID, aspirin.
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:   analysis of variance

CFA

:   complete Freund's adjuvant

H~2~S

:   hydrogen sulfide

IL-1*β*

:   interleukin-1 beta

K~ATP~

:   ATP-sensitive potassium channel

KC/CXCL1

:   keratinocyte-derived chemokine

MPO

:   myeloperoxidase

NO

:   nitric oxide

NSAIDs

:   nonsteroidal anti-inflammatory drugs

PGE~2~

:   prostaglandin E~2~

TNF-*α*

:   tumor necrosis factor
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